The RadiCaL Study: Testing the Addition of a New Anti-Cancer Drug to the Usual Treatment for Advanced Renal Cell Cancer that has Spread to the Bone

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.

In order to participate you must meet the following criteria:

• Have documented histologic or cytologic diagnosis of renal cell cancer (RCC).
• Have presence of at least 2 metastatic bone lesions not treated with prior radiation.
• Have no prior therapy with radium-223 dichloride or systemic radiotherapy.
• Are not pregnant or nursing.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.